
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Researchers stop brain cell death in Alzheimer’s mice
The research team led by Prof. Bart De Strooper (VIB-KU Leuven/UK Dementia Research Institute), and Dr Sriram Balusu (VIB-KU Leuven) has finally...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

AI helps classifying brain tumours during surgery
The findings presented in Nature by a team led by Jeroen De Ridder from UMC Utrecht demonstrate the potential feasibility of obtaining molecular...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...